1Rose AN,Pepin F,Russo C ,et al. Osteoactivin promotes breast cancer metastasis to bone. Molecular Cancer Research, 2007,5 (10) :1001 - 1014.
2Moharita AL,Taborga M, Corcoran KE,et al. Rameshwar. SDF - 1 α regulation in breast cancer ceils contacting bone marrow stroma is critical for normal hematopoiesis. Blood, 2006,108 (10) :3245 -3252.
3Rameshwar P. Implication of possible therapies targeted for the tachykinergic system with the biology of neurokinin receptors and emerging related proteins. Recent Patents on CNS Drug Discovery, 2007,2(1) :79 - 84.
4Murthy RG, Greco SJ,Taborga M,et al. Tacl regulation by RNA - binding protein and miRNA in bone marrow stroma: implication for hematopoietic activity. Brain, Behavior, and Immunity, 2008,22 (4) :442 -450.
5Rao G,Patel PS, Idler SP, et al. Facilitating role of preprotachykinin -I gene in the integration of breast cancer cells within the stromal compartment of the bone marrow : a model of early cancer progression. Cancer Research, 2004,64 ( 8 ) :2874 - 2881.
6Bandari PS, Qian J, Yehia G, et al. Hematopoietic growth factor inducible neurokinin - 1 type: a transmembrane protein that is similar to neurokinin 1 interacts with substance P. Regulatory Peptides,2003,111(1 -3) :169 -178.
7Patel H J, Ramkissoon SH, Patel PS, et al. Transformation of breast cells by truncated neurokinin - 1 receptor is secondary to activation by preprotachykinin - A peptides. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102 (48) : 17436 - 17441.
8Corcoran KE,Rameshwar P. Nuclear factor - KB accounts for the repressor effects of high stromal cell -derived factor- 1α levels on Tacl expression in nontumorigenic breast cells. Molecular Cancer Research, 2007, 5 (4) :373 - 381.
9Kretzschmar M. Transforming growth factor - β and breast cancer: transforming growth factor - β/SMAD signaling defects and cancer. Breast Cancer Research, 2000,2 (2) : 107 - 115.
10Yang J, Song K, Krebs TL,et al. Rb/E2F4 and Smad2/3 link survivin to TGF - β - induced apoptosis and tumor progression. Oncogene, 2008, 27 (40):5326 - 5338.
